Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 816 results for "gilead sciences"

ArticleGilead halts study of GS-5745 for ulcerative colitis after it fails to show efficacy23-09-2016
Pharma Letter

BRIEF-Gilead sciences, WHO announce 5-year visceral leishmania...

Sept 27 Gilead Sciences * Gilead Sciences and the World Health Organization announce five-year visceral leishmaniasis collaboration * Partnership with World Health Organization to expand access to diagnostic services and treatment for ... Reuters UK, 30 minutes ago

499 images for gilead sciences

American Banking News, 8 hours ago
Mideast Time, 9 hours ago
Octafinance, 7 hours ago
Octafinance, 7 hours ago
Investor's Business Daily, 6 days ago
Denver Post, 1 week ago
Bidness Etc, 2 weeks ago
Octafinance, 2 weeks ago
Octafinance, 1 week ago
Schaeffers Research, 3 hours ago

Gilead 'Paralyzed' On Staggering hepatitis C Market

Leerink Swann analyst Geoffrey Porges is "tired of waiting" for Gilead Sciences ( GILD ) to acknowledge slowing hepatitis C patient volume and competition from rivals AbbVie and Merck. Porges downgraded Gilead stock to a market perform rating ...
 Investor's Business Daily1 hour ago Gilead 'Paralyzed' On Likely hepatitis C Share Loss To AbbVie, Merck  BioSpace1 hour ago
CEOWorld Magazine

Gilead Sciences: Tired of Waiting

September 27, 2016 at 10:00 AM EDT Gilead Sciences: Tired of Waiting Leerink's Geoffrey Porges and Bradley Canino cut shares of Gilead Sciences ( GILD ) to Market Perform from Outperform, arguing that they're "tired of waiting." They
 Marketplace6 hours ago Gilead Sciences: A Slight Uplift for R&D Strategy?  Marketplace1 day ago Gilead Sciences Feb 80 - 90, 1X2, call spread for $1.78, 3000X  International Business Times1 day ago Cramer Advises His Viewers On Gilead Sciences And Monsanto  Benzinga.com4 days ago

Allergan Validates Gilead Sciences' NASH Pipeline

Allergan (NYSE: AGN ) set the biotech world buzzing with the aggressive premium paid to acquire a toehold in the competitive race to produce a functional treatment for NASH (non-alcoholic steatohepatitis). AGN bold string of acquisitions positions ...
 Seeking Alpha5 hours ago Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma  Benzinga.com6 days ago

5 Great Ways To Potentially Earn Fantastic Yield On Gilead's Crazy Cheap Shares

Click to enlarge Gilead Sciences (NASDAQ: GILD ) has proven itself phenomenally successful at generating mountains of shareholder wealth over its 29-year history. GILD Total Return Price data by YCharts That being said, it's ...
 Seeking Alpha9 hours ago

Sell Twitter, Buy Gilead And More Fast Money Picks For September 23

On CNBC's Fast Money Final Trade , Tim Seymour recommended a long position in Gilead Sciences, Inc. (NASDAQ: GILD ). He thinks the stock is cheaper than its peers. David Seaburg believes Twitter Inc (NYSE: TWTR ) is going lower. He wants to sell ...
 Benzinga.com4 days ago
Motley Fool

Gilead Sciences Inc.'s Biggest Win in 2016 So Far

Image source: . Gilead Sciences ( NASDAQ:GILD ) hasn't exactly had the best 2016. Shares of the biotech are down about 20% year to date as sales of its hepatitis C drugs slumped from pricing pressure, and as doctors have worked through the ...
 Motley Fool5 days ago
Motley Fool

The Pros and Cons of Buying Gilead Sciences Stock

Image source: via Flickr. Gilead Sciences ( NASDAQ:GILD ) is a biotech Goliath generating $30 billion in annualized sales and $14 billion in annualized net income. However, shares have fallen in the past year. Does Gilead ...
 Motley Fool5 days ago
Seeking Alpha

The Process Of Valuation: Gilead Sciences

Warren Buffett once said: An investor's success is in direct proportion to the degree to which he understands the investment. Like a lot of the Oracle's statements, this bite-sized morsel of wisdom seems sensible at first, but turns out to ...
 Seeking Alpha5 days ago

M&A Action Starts To Move Gilead

Gilead Sciences (NASDAQ: GILD ) is enjoying a well-deserved rise due to the M&A activities going on in the biotech sector. It is interesting that the market needed to see some movement from other major players in the industry to realize that the ...
 Seeking Alpha6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
Get updated on latest news & your favorite topics right in your inbox!
More     Less